Is Your Portfolio Healthy? Don't Touch This Stock With a Ten-Foot Pole!

NASDAQ: CDMO | Avid Bioservices, Inc. News, Ratings, and Charts

CDMO – Amidst lingering economic uncertainties, pharma contract development company Avid Bioservices (CDMO) has been flashing red flags with deteriorating financial results in the last reported quarter and bleak prospects. Therefore, I think this fundamentally weak stock might be best avoided. Keep reading…

The US stock market is facing a bumpy ride as it grapples with the persistent stress in the banking sector, compounded by the heightened fear over the US debt ceiling. The market turbulence is further fueled by concerns over high consumer inflation, which despite cooling off from its peak in June, remains above the Federal Reserve’s target.

Given the uncertainty, it is crucial to monitor your portfolio’s health. Therefore, Avid Bioservices, Inc. (CDMO - Get Rating), which is currently trading below its 50-day and 200-day moving averages, could be best avoided, and in this article, I will explain why.

The stock declined 3.1% intraday to close the last trading session at $18.

Here’s what could shape CDMO’s performance in the near term:

Weak Financials

CDMO’s total operating expenses rose 22.2% year-over-year to $7.11 million for the fiscal third quarter that ended January 31, 2023. The increase was primarily due to increases in compensation and benefits, legal, accounting, and other professional expenses.

Its operating income dropped by 16.9% from the prior-year quarter to $2.72 million. Its adjusted net income declined 21.5% year-over-year to $4.28 million. Also, its EPS decreased 300% from the prior-year quarter to $0.01.

Bleak EPS Growth Expectation

Analysts expect CDMO’s EPS to decline 44.7% year-over-year to $0.19 in the fiscal year 2023. Its EPS for the fiscal fourth quarter ending April 2023 is expected to decrease 75.2% from the previous-year quarter to $0.02.

Stretched Valuations

In terms of forward non-GAAP PEG, CDMO is currently trading at 6.32x, which is 203% higher than the industry average of 2.08x. Its forward P/S multiple of 7.59 is 87.4% higher than the industry average of 4.05.

Its forward EV/Sales multiple of 8.41x is also 132.2% higher than the industry average of 3.62x and its forward P/B of 6.27x is 129.4% higher than the industry average of 2.73x.

POWR Ratings Reflect Bleak Outlook

CDMO has an overall rating of F, translating to a Strong Sell in our proprietary POWR Ratings system. The POWR Ratings are calculated considering 118 distinct factors, with each factor weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight distinct categories. The stock has a D grade for Value consistent with its premium valuation.

Its D grade in Growth is in sync with its weak performance in the latest quarter. Its 24-month beta of 1.91 justifies its D grade in Stability.

CDMO is ranked last among 164 stocks in the D-rated Medical – Pharmaceuticals industry.

Click here to access CDMO’s Sentiment, Momentum, and Quality grades.

Bottom Line

CDMO is trading below its 50-day and 200-day moving averages of $17.74 and $16.89, respectively, suggesting a downtrend.

The company’s recent financial performance, including declining income and bleak EPS prospects, as well as its stretched valuations and high beta value, suggest a gloomy outlook.

So, it might be best to avoid investing in CDMO now.

Stocks to Consider Instead of Avid Bioservices, Inc. (CDMO)

Unfortunately, the odds of CDMO outperforming in the weeks and months ahead are significantly compromised. However, many good stocks in the Medical- Pharmaceuticals industry have impressive POWR Ratings. So, consider these three A-rated (Strong Buy) stocks instead:

Novartis AG ADR (NVS - Get Rating)

Novo Nordisk A/S ADR (NVO - Get Rating)

Takeda Pharmaceutical Co. Ltd. ADR (TAK - Get Rating)

The Bear Market is NOT Over…

That is why you need to discover this timely presentation with a trading plan and top picks from 40 year investment veteran Steve Reitmeister:

REVISED: 2023 Stock Market Outlook > 

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


CDMO shares were trading at $17.92 per share on Thursday morning, down $0.08 (-0.44%). Year-to-date, CDMO has gained 30.14%, versus a 6.97% rise in the benchmark S&P 500 index during the same period.


About the Author: Kritika Sarmah


Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CDMOGet RatingGet RatingGet Rating
NVSGet RatingGet RatingGet Rating
NVOGet RatingGet RatingGet Rating
TAKGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Stocks in Unchartered Territory

The S&P 500 (SPY) is in unchartered territory given how it is flirting with the 200 day moving average. This makes the outlook uncertain. Steve Reitmeister tries to make sense of it all in this timely commentary.

Stock Market Alert: Disaster Averted?

Investors have been sitting on pins and needles as the S&P 500 (SPY) broke below the 200 day moving average. However it appears that disaster may have been averted with the rally this week. Steve Reitmeister shares the full story in the commentary to follow...

Bear Market Watch: Week 2

Why does Steve Reitmeister believe the S&P 500 (SPY) needs to be back above 5,747 by 3/31 or it spells trouble for investors? Read on below for the full answer...

Has the Next Bear Market Already Arrived?

The recent break below the 200 day moving average for the S&P 500 (SPY) has a lot of investors worried that the next bear market has already arrived. Investment expert Steve Reitmeister shares his timely views along with a trading plan to stay on the right side of the action.

How Low Will Stocks Go?

The S&P 500 (SPY) is testing the 200 day moving average with fears on tariffs and GDP that could push them even lower. Now is a good time to hear what 40 year investment veteran Steve Reitmeister says about the market outlook and odds of bear market.

Read More Stories

More Avid Bioservices, Inc. (CDMO) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CDMO News